MX2021012604A - Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas. - Google Patents

Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.

Info

Publication number
MX2021012604A
MX2021012604A MX2021012604A MX2021012604A MX2021012604A MX 2021012604 A MX2021012604 A MX 2021012604A MX 2021012604 A MX2021012604 A MX 2021012604A MX 2021012604 A MX2021012604 A MX 2021012604A MX 2021012604 A MX2021012604 A MX 2021012604A
Authority
MX
Mexico
Prior art keywords
treatment
viral
inhibitor
bacterial infections
novel mek
Prior art date
Application number
MX2021012604A
Other languages
English (en)
Spanish (es)
Inventor
Oliver Planz
Original Assignee
Atriva Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atriva Therapeutics Gmbh filed Critical Atriva Therapeutics Gmbh
Publication of MX2021012604A publication Critical patent/MX2021012604A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2021012604A 2019-04-16 2020-04-16 Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas. MX2021012604A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU101183A LU101183B1 (en) 2019-04-16 2019-04-16 Novel mek-inhibitor for the treatment of viral and bacterial infections
PCT/EP2020/060692 WO2020212478A1 (en) 2019-04-16 2020-04-16 Novel mek-inhibitor for the treatment of viral and bacterial infections

Publications (1)

Publication Number Publication Date
MX2021012604A true MX2021012604A (es) 2021-11-12

Family

ID=66554457

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012604A MX2021012604A (es) 2019-04-16 2020-04-16 Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.

Country Status (13)

Country Link
US (1) US12350244B2 (https=)
EP (1) EP3955908B1 (https=)
JP (2) JP2022529343A (https=)
KR (1) KR20210153642A (https=)
CN (1) CN114007598A (https=)
AU (1) AU2020258002B2 (https=)
BR (1) BR112021020605A2 (https=)
CA (1) CA3136171A1 (https=)
EA (1) EA202192454A1 (https=)
ES (1) ES3012533T3 (https=)
LU (1) LU101183B1 (https=)
MX (1) MX2021012604A (https=)
WO (1) WO2020212478A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3912623B1 (en) * 2020-05-20 2024-07-31 Atriva Therapeutics GmbH Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
EP4186500A1 (en) * 2021-11-24 2023-05-31 Atriva Therapeutics GmbH Mek inhibitors for the prevention and treatment of long covid syndrome
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs
CN119931962B (zh) * 2025-04-07 2025-08-05 北京华诺泰生物医药科技有限公司 一种人偏肺病毒的培养方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040237A1 (en) * 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
KR20020012315A (ko) * 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
WO2014056894A1 (en) 2012-10-08 2014-04-17 Westfaelische Wilhelms-Universitaet Muenster Mek inhibitors in the treatment of virus diseases
CN113398271A (zh) 2014-05-16 2021-09-17 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
EP3973960B1 (en) * 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
KR20220074869A (ko) * 2019-08-27 2022-06-03 아트리바 테라퓨틱스 게엠베하 Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합
JP7802365B2 (ja) * 2019-10-08 2026-01-20 アトリバ セラピューティクス ゲーエムベーハー ハンタウイルス感染症の処置のためのｍｅｋ阻害剤
EP3912623B1 (en) * 2020-05-20 2024-07-31 Atriva Therapeutics GmbH Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm

Also Published As

Publication number Publication date
JP2025124703A (ja) 2025-08-26
KR20210153642A (ko) 2021-12-17
EA202192454A1 (ru) 2022-03-22
JP2022529343A (ja) 2022-06-21
LU101183B1 (en) 2020-10-16
CA3136171A1 (en) 2020-10-22
CN114007598A (zh) 2022-02-01
US20220193017A1 (en) 2022-06-23
AU2020258002B2 (en) 2025-12-18
AU2020258002A1 (en) 2021-11-18
ES3012533T3 (en) 2025-04-09
BR112021020605A2 (pt) 2021-12-07
EP3955908A1 (en) 2022-02-23
US12350244B2 (en) 2025-07-08
WO2020212478A1 (en) 2020-10-22
EP3955908C0 (en) 2025-01-22
EP3955908B1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
EA202090693A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
AU2020342649B2 (en) Compositions and methods for the treatment of viral infections
PH12022550033A1 (en) Compounds useful to treat influenza virus infections
GEP20227374B (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
AU2012332832A8 (en) Compositions useful for the treatment of viral diseases
MX2019002978A (es) Composiciones que comprenden una bacteria no patogena y metodos para proteger plantas y animales anfitriones contra enfermedades micoticas, bacterianas y virales.
MX2021007602A (es) Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b.
MX2022010926A (es) Compuestos para su uso en infecciones viricas.
EP4022072A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
EP4213820A4 (en) METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS
EP4093758A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF VIRAL INFECTIONS
MX2024013042A (es) Compuestos para el tratamiento de la infeccion por arenavirus.
PH12020551944A1 (en) Reverse peptide vaccine
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
WO2021019235A3 (en) Hantavirus antigenic composition
WO2022040238A3 (en) Engineered arenavirus glycoprotein compositions and methods of use thereof
EP4367086A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF VIRUS INFECTIONS
IL316175A (en) Preparations and methods for preventing and treating rabies virus infection
WO2019039781A3 (ko) 신규한 에로모나스 살모니시다 박테리오파지 ａｅｒ-ｓａｐ-2 및 이의 에로모나스 살모니시다 균 증식 억제 용도
EP4161646A4 (en) COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTIONS
WO2018117462A3 (ko) 신규한 비브리오 파라헤몰리티쿠스 박테리오파지 Ｖｉｂ-ＰＡＰ-4 및 이의 비브리오 파라헤몰리티쿠스 균 증식 억제 용도
HK40101531A (en) Methods and compositions for treating viral infection
HK40081952A (en) Method and compositions for treating, preventing or limiting the occurrence of viral infection
HK40096243A (en) Compositions and methods for treating viral infection